A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Abroad (travel likely)RecruitingPHASE1
Conditions
TP53 Y220C Mutation · Advanced Solid Tumors
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
HealthOne Denver, Denver, Colorado, United States
Florida Cancer Specialists, Orlando, Florida, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
SCRI at Mary Crowley, Dallas, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
Study leads
Vivek Subbiah, MD
Study Chair
SCRI